Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer

This single-arm pilot study (NCT03329937) evaluated neoadjuvant niraparib antitumor activity and safety in patients with localized HER2-negative, BRCA-mutated breast cancer. Twenty-one patients received niraparib 200 mg once daily in 28-day cycles. After 2 cycles, tumor response (≥30% reduction from...

Descripción completa

Detalles Bibliográficos
Autores principales: Spring, Laura M., Han, Hyo, Liu, Minetta C., Hamilton, Erika, Irie, Hanna, Santa-Maria, Cesar A., Reeves, James, Pan, Peng, Shan, Ming, Tang, Yongqiang, Graham, Julie R., Hazard, Sebastien, Ellisen, Leif W., Isakoff, Steven J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402431/
https://www.ncbi.nlm.nih.gov/pubmed/35788722
http://dx.doi.org/10.1038/s43018-022-00400-2
_version_ 1784773175222992896
author Spring, Laura M.
Han, Hyo
Liu, Minetta C.
Hamilton, Erika
Irie, Hanna
Santa-Maria, Cesar A.
Reeves, James
Pan, Peng
Shan, Ming
Tang, Yongqiang
Graham, Julie R.
Hazard, Sebastien
Ellisen, Leif W.
Isakoff, Steven J.
author_facet Spring, Laura M.
Han, Hyo
Liu, Minetta C.
Hamilton, Erika
Irie, Hanna
Santa-Maria, Cesar A.
Reeves, James
Pan, Peng
Shan, Ming
Tang, Yongqiang
Graham, Julie R.
Hazard, Sebastien
Ellisen, Leif W.
Isakoff, Steven J.
author_sort Spring, Laura M.
collection PubMed
description This single-arm pilot study (NCT03329937) evaluated neoadjuvant niraparib antitumor activity and safety in patients with localized HER2-negative, BRCA-mutated breast cancer. Twenty-one patients received niraparib 200 mg once daily in 28-day cycles. After 2 cycles, tumor response (≥30% reduction from baseline) by MRI was 90.5% and 40.0% (6 of 15) of patients who received only niraparib (2–6 cycles) had pathological complete response; no new safety signals were identified. High niraparib intratumoral concentration was observed.
format Online
Article
Text
id pubmed-9402431
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group US
record_format MEDLINE/PubMed
spelling pubmed-94024312022-08-26 Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer Spring, Laura M. Han, Hyo Liu, Minetta C. Hamilton, Erika Irie, Hanna Santa-Maria, Cesar A. Reeves, James Pan, Peng Shan, Ming Tang, Yongqiang Graham, Julie R. Hazard, Sebastien Ellisen, Leif W. Isakoff, Steven J. Nat Cancer Brief Communication This single-arm pilot study (NCT03329937) evaluated neoadjuvant niraparib antitumor activity and safety in patients with localized HER2-negative, BRCA-mutated breast cancer. Twenty-one patients received niraparib 200 mg once daily in 28-day cycles. After 2 cycles, tumor response (≥30% reduction from baseline) by MRI was 90.5% and 40.0% (6 of 15) of patients who received only niraparib (2–6 cycles) had pathological complete response; no new safety signals were identified. High niraparib intratumoral concentration was observed. Nature Publishing Group US 2022-07-04 2022 /pmc/articles/PMC9402431/ /pubmed/35788722 http://dx.doi.org/10.1038/s43018-022-00400-2 Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Brief Communication
Spring, Laura M.
Han, Hyo
Liu, Minetta C.
Hamilton, Erika
Irie, Hanna
Santa-Maria, Cesar A.
Reeves, James
Pan, Peng
Shan, Ming
Tang, Yongqiang
Graham, Julie R.
Hazard, Sebastien
Ellisen, Leif W.
Isakoff, Steven J.
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
title Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
title_full Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
title_fullStr Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
title_full_unstemmed Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
title_short Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
title_sort neoadjuvant study of niraparib in patients with her2-negative, brca-mutated, resectable breast cancer
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402431/
https://www.ncbi.nlm.nih.gov/pubmed/35788722
http://dx.doi.org/10.1038/s43018-022-00400-2
work_keys_str_mv AT springlauram neoadjuvantstudyofniraparibinpatientswithher2negativebrcamutatedresectablebreastcancer
AT hanhyo neoadjuvantstudyofniraparibinpatientswithher2negativebrcamutatedresectablebreastcancer
AT liuminettac neoadjuvantstudyofniraparibinpatientswithher2negativebrcamutatedresectablebreastcancer
AT hamiltonerika neoadjuvantstudyofniraparibinpatientswithher2negativebrcamutatedresectablebreastcancer
AT iriehanna neoadjuvantstudyofniraparibinpatientswithher2negativebrcamutatedresectablebreastcancer
AT santamariacesara neoadjuvantstudyofniraparibinpatientswithher2negativebrcamutatedresectablebreastcancer
AT reevesjames neoadjuvantstudyofniraparibinpatientswithher2negativebrcamutatedresectablebreastcancer
AT panpeng neoadjuvantstudyofniraparibinpatientswithher2negativebrcamutatedresectablebreastcancer
AT shanming neoadjuvantstudyofniraparibinpatientswithher2negativebrcamutatedresectablebreastcancer
AT tangyongqiang neoadjuvantstudyofniraparibinpatientswithher2negativebrcamutatedresectablebreastcancer
AT grahamjulier neoadjuvantstudyofniraparibinpatientswithher2negativebrcamutatedresectablebreastcancer
AT hazardsebastien neoadjuvantstudyofniraparibinpatientswithher2negativebrcamutatedresectablebreastcancer
AT ellisenleifw neoadjuvantstudyofniraparibinpatientswithher2negativebrcamutatedresectablebreastcancer
AT isakoffstevenj neoadjuvantstudyofniraparibinpatientswithher2negativebrcamutatedresectablebreastcancer

Ejemplares similares